StockDuty ← Dashboard Oct 30, 2026 12:02 AM ET
SignalCorporate

Illumina forecasts 2026 EPS of $5.40-$5.45 while raising revenue outlook to $4.64B-$4.66B

Illumina raised revenue outlook to $4.64B-$4.66B and forecast 2026 EPS of $5.40-$5.45.

What happened: Illumina raised its full-year revenue guidance to $4.64 billion to $4.66 billion and guided 2026 diluted EPS of $5.40 to $5.45, after Q3 revenue, margin and EPS came in above its guidance range. Key numbers: Q3 revenue $1.17 billion; diluted EPS $1.44, up 7% Why it matters: Management attributed the raise to clinical sequencing demand and NovaSeq X placements, and said Q4 strength is driven by consumable revenue on a larger installed base. Analysts pressed on clinical growth durability, pull-forward risk and China uncertainty, with a full 2027 guide deferred to the Q4 call. Market: +0.4% today ($290.06), +115.9% YTD, 0.7x vol — as of 23:45 UTC Verified: Q3_2026 (Oct 29) EPS $1.62 vs $1.36 est, +19.3% beat; next print ~Jan 28 Coverage: 4 outlets in 24h
Illumina raised its full-year revenue guidance to $4.64 billion to $4.66 billion and guided 2026 diluted EPS of $5.40 to $5.45, after Q3 revenue, margin and EPS came in above its guidance range.
Management attributed the raise to clinical sequencing demand and NovaSeq X placements, and said Q4 strength is driven by consumable revenue on a larger installed base. Analysts pressed on clinical growth durability, pull-forward risk and China uncertainty, with a full 2027 guide deferred to the Q4 call. Market: +0.4% today ($290.06), +115.9% YTD, 0.7x vol — as of 23:45 UTC Verified: Q3_2026 (Oct 29) EPS $1.62 vs $1.36 est, +19.3% beat; next print ~Jan 28
Sources